RESEARCH LIBRARY
Start with a question.
Stay for the evidence.
Plain-language guides that keep the study design, uncertainty, and original sources in view.
What is THC? A research-first guide
How delta-9-tetrahydrocannabinol interacts with the body, what researchers measure, and where simple explanations fall short.
What is CBD? Claims, evidence, and approved medicine
CBD is not simply non-intoxicating THC. Its pharmacology, evidence, interactions, and regulation require their own explanation.
THCA vs. THC: chemistry before marketing
The acidic precursor and its decarboxylated product are related, but labels and legal shorthand often obscure the chemistry.
The endocannabinoid system, without the hype
Receptors, signaling molecules, enzymes, and the limits of the master-regulator metaphor.
Cannabinoid hyperemesis syndrome: signs and evidence
A recurrent vomiting syndrome associated with prolonged cannabis exposure—and why recognition matters.
Cannabis side effects and risk factors
A structured overview of short-term effects, longer-term associations, and groups that face higher risk.
Epidiolex: what an approved CBD medicine proves
The indications, evidence, controls, and monitoring behind the first FDA-approved purified cannabidiol drug.
Dronabinol: synthetic THC as a regulated medicine
Why an approved cannabinoid drug should be evaluated separately from the cannabis plant and consumer products.
Nabilone: evidence and clinical context
A concise guide to the synthetic cannabinoid medicine, its uses, and its limitations.
How to read a cannabis study
A practical framework for separating a promising signal from a clinically useful result.
Cannabis history: medicine, prohibition, and research
A source-led timeline of changing uses, institutions, laws, and scientific questions.
Cannabis genetics beyond strain names
Chemotypes, inheritance, environment, and why commercial names are weak scientific identifiers.
Cannabis and chronic pain: what the evidence actually measures
Some cannabinoid formulations produce small short-term changes for some pain outcomes, alongside adverse effects and major evidence gaps.
Cannabinoids and chemotherapy nausea: where they fit
Approved cannabinoid medicines exist for treatment-related nausea, but modern guidelines distinguish refractory symptoms from first-line care.
Cannabinoids for multiple-sclerosis spasticity
Evidence and guidance are specific to symptoms, regulated formulations, prior treatment, and continued response.
CBD and epilepsy: one approved medicine, defined syndromes
Randomized trials support purified prescription cannabidiol for specific seizure disorders; that conclusion has precise boundaries.
Cannabis for sleep: small signals, large uncertainty
Studies often involve people with chronic pain rather than primary insomnia, and newer synthesis finds very uncertain clinical benefit.
Cannabis and driving: impairment, testing, and uncertainty
THC can impair skills needed for driving, while a blood or urine result cannot by itself measure present impairment.
Cannabis during pregnancy and breastfeeding
Major health agencies advise avoiding THC, CBD, and cannabis while pregnant or breastfeeding because safety has not been established and potential harms remain.
Cannabis, psychosis, and mental health
Cannabis exposure is associated with psychosis risk, especially with earlier and more frequent use, but individual outcomes cannot be predicted from association alone.
CBD interactions and liver risk
CBD can change medication exposure and affect the liver; retail availability does not make it interaction-free.
Cannabis edibles and accidental child poisoning
Delayed effects, concentrated THC, and familiar-looking packaging create a preventable poisoning risk for children.
THC half-life and detection windows are different questions
Impairment, blood concentration, metabolism, and a positive test follow different timelines, so no single countdown answers them all.
Cannabis use disorder and withdrawal
Frequent cannabis use can become difficult to control, and stopping after sustained exposure can produce a recognized withdrawal syndrome.
Nabiximols (Sativex): formulation, evidence, and approval
A standardized THC:CBD oromucosal medicine has defined indications in some countries and is not interchangeable with consumer cannabis products.
Cannabis and ADHD: evidence does not support self-treatment
Interest and self-reported use are not the same as clinical evidence; established ADHD guidelines do not recommend cannabis as treatment.
Cannabis, blood pressure, and cardiovascular risk
Acute heart-rate and blood-pressure changes are documented, while longer-term cardiovascular risk estimates remain affected by product and population differences.
Raphael Mechoulam and the foundations of cannabinoid science
The chemist's work helped identify THC, clarify cannabinoid structures, and open the path to discovery of the endocannabinoid system.
How scientists identified THC
Isolation, structural chemistry, stereochemistry, and pharmacology turned a plant effect into a testable molecular question.
From THC to the endocannabinoid system: a discovery timeline
Cannabinoid chemistry led researchers from a plant molecule to receptors, endogenous ligands, and a new signaling field.